HBA Boston presents

Biosimilars - A New Innovation Pathway to Affordable Medicine

Event description
Changing regulations and a looming biotech patent cliff have created enormous opportunity in the global market for biosimilars to boom over the next few years. Are they generics or copycat drugs? No, but they are expected to slash the cost of some of our most widely used drugs by nearly half. Join us to find out how biosimilars could revolutionize the concept of cost-effective healthcare, and the regulatory and commercial challenges posed by this innovation pathway.

The panel represents diverse perspectives from the life sciences ecosystem and will discuss the following key topics: how biosimilars differ from generic products, FDA regulations and the cost of developing a biosimilar, and the implications for pharma, physicians, and patients.

Our esteemed panelists include: Susan Dexter, principal consultant, Latham Biopharm, Magdalena Leszcyniecka, president and CEO, STC Biologics, Inc; Michael Wyand, chief technology officer, EPIRUS Biopharmaceuticals and moderator, Marie Sanchirico, medical managed care director, Genzyme, A Sanofi Company.

Learning objectives
1. Define biosimilars and why they are considered a new innovation pathway
2. Identify the main challenges surrounding biosimilars from a clinical, regulatory and commercial standpoint
3. Identify the implications for key stakeholders by the introduction of biosimilars into the marketplace

5:30 PM - 6:30 PM     Registration and networking
6:30 PM - 7:45 PM     Panel discussion, Q&A
7:45 PM - 8:30 PM     Networking  and additional discussion time

Event location
Genzyme, A Sanofi Company, Roscoe Brady Auditorium
500 Kendall Street
Cambridge, MA, 02142
617 252 7500


Special instructions:
Parking is in public garage close to building. Accessible from the Kendall T station.



Susan Dexter
Principal consultant, Latham Biopharma

Magdalena Leszczyniecka
President and CEO, STC Biologics

Marie Sanchirico
Medical managed care director, Genzyme, a Sanofi Company

Michael Wyand
Chief technical officer, EPIRUS Biopharmaceuticals

Registration information
Event is open to: HBA members and nonmembers
Online registration deadline: June 9, 2015
Onsite (walk-in) registration: Is allowed

Is capacity limited? Yes
Space is limited to 100 registrants.

Is this event refundable? Yes
If yes, requests must be submitted in writing to events@hbanet.org by June 3, 2015; no refunds are available after this date.

Event questions/support
- Chapter contact for event: Sudipta Mahajan at sudipta_mahajan@vrtx.com or
- Membership questions: membership@hbanet.org or 973-575-0606 ext 1
- Online registration assistance: events@hbanet.org or 973-575-0606 ext 3

Visit us online

Featured speakers
Learning objectives


Registration information

The registration button at the bottom of the page will not show if online registration has closed or if the event has reached capacity. If you are a guest and the registration button is not showing, it may be that this is a member-only event. Read more about the benefits of membership or contact us about membership.

The HBA will make reasonable modifications to policies and programs to ensure that people with special needs have an equal opportunity to enjoy all of its programs. Contact us if you require special accommodations for this event.


 Price LevelRegular
Collapse group

Registration: Regular Registration

 Member - Euro€17.00
 Non-Member - Euro€34.00

By registering for this event, you acknowledge that you may be photographed, videotaped and/or audio-taped during the course of the meeting and hereby give permission for your image, voice, or survey comments to be used in education, training, promotion and/or trade and communications media by the Healthcare Businesswomen's Association in any and all media throughout the world, without restriction as to frequency or duration of usage.